WILMINGTON, Del.--Bioinformatics will be used to develop diagnostic and therapeutic targets under terms of a new agreement between VIMRX Pharmaceuticals here and Columbia University. The development work will be based on two cancer genes, recently identified by scientists at the Columbia Genome Center, that control non-Hodgkin's lymphoma and multiple myeloma.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.